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Abstract: In respiratory syncytial virus (RSV) disease the balance between the innate and 
adaptive immune responses determines the expression of the pathological phenotype favoring 
the development of acute bronchiolitis, and in certain children the development of recurrent 
wheezing. While humoral antibody plays a major role in protection against disease, T-cell 
immunity targeted to viral proteins appears to terminate viral infection. At the moment, treatment 
modalities for acute RSV infection do not effectively modify the course of the disease, and RSV 
vaccine development has shown conﬂ  icting results. To date, however, passive immunoprophy-
laxis with monoclonal antibodies is the only strategy that has demonstrated consistent efﬁ  cacy 
in reducing RSV hospitalizations in high-risk children. The potential beneﬁ  t of new strategies 
for prevention and treatment of RSV infections should be evaluated with respect to both the 
acute infection as well as the chronic respiratory manifestations induced by RSV.
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The virus
Respiratory syncytial virus (RSV) is a member of the Pneumovirus genus, Paramyxovi-
dae family. Its negative-sense single-stranded RNA genome contains 10 genes that 
encode 11 proteins. Five of these proteins are involved in RNA synthesis: the nucleo-
capside N protein, the L protein (polymerase), the phosphoprotein P, and the M2-1 
and M2-2 proteins (Collins and Crowe 2007). Four other RSV proteins are associated 
with the lipid bilayer to form the viral envelope: the matrix M protein, two glycosyl-
ated surface proteins, the F and G proteins, and a small hydrophobic SH protein. The 
F and G proteins are crucial for the infectivity and pathogenesis of the virus. The G 
protein mediates attachment of the virus to respiratory epithelial cells, whereas the F 
(fusion) protein facilitates entry of the virus by fusing viral and cellular membranes 
and insertion of the RNA into the host cell inducing the formation of the characteristic 
syncytia (Hall 2000). The F and G proteins carry the antigenic determinants that elicit 
the production of neutralizing antibodies by the host. The remaining two proteins, NS1 
and NS2, are nonstructural accessory proteins involved in modulating the host response 
to infection. NS1 and NS2 are abundantly present in infected cells and confer virus 
resistance to type-I interferons enhancing viral replication and survival (Spann et al 
2004). Compared with other close relatives, in RSV the M2-1 protein is essential for 
the viability of the virus and in its absence transcription terminates nonspeciﬁ  cally 
and results in expression of NS1 and NS2 alone (Fearns and Collins 1999).
RSV displays minimal antigenic heterogeneity; however, there are two major 
RSV subtypes, A and B, which cocirculate each year. Much of the antigenic diversity 
between and within RSV subtypes is due to variations in the G glycoprotein, with as 
little as 35% homology between G glycoprotein of strains A and B (Johnson et al 2004). Biologics: Targets & Therapy 2008:2(3) 434
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It is not clear whether one subtype is more virulent than 
the other (Devincenzo 2004; Chavez-Bueno et al 2005). 
Antibody responses to the F protein are often cross-reactive 
for RSV A and B, while antibody responses to the G protein 
are subtype speciﬁ  c.
Epidemiology
RSV is the leading viral pathogen responsible for lower 
respiratory tract infection (LRTI) requiring hospitalization 
in infants and young children worldwide. In US alone, it is 
estimated that at least 140,000 hospitalizations can be attrib-
uted to RSV LRTI each year (Shay et al 1999). The reservoir 
is exclusively human. RSV outbreaks occur annually and 
predictably, lasting from late fall through early spring in 
temperate climates but it can circulate all year long in areas 
close to the equator (Mejias et al 2005a).
The spectrum of RSV disease is wide, ranging from mild 
upper respiratory tract infection (URI), LRTI, to respiratory 
failure. Primary RSV infection is almost always symptomatic. 
Infection with RSV is one of the most common diseases of 
childhood. It is responsible for 50%–90% of children hospi-
talized for bronchiolitis and for 5%–40% due to pneumonia 
(Psarras et al 2004). Approximately two-thirds of infants are 
infected with RSV during the ﬁ  rst year of life, and 90% have 
been infected one or more times by 2 years of age (Glezen et al 
1986). Studies conducted in many different countries over the 
last 20 years have consistently demonstrated that premature 
infants and children with chronic lung disease (CLD) and con-
genital heart disease (CHD) are at greater risk for severe RSV 
infection. In addition, RSV has been associated with severe 
respiratory illness in the elderly, immunocompromised patients 
as well as in previously healthy adults (Hall et al 1978).
In addition to the acute morbidity, different studies have 
shown over the past 10 years that young children who had 
RSV LTRI are at increased risk for developing recurrent 
wheezing and possibly asthma later in childhood (Stein et al 
1999; Sigurs et al 2005).
RSV treatment
While signiﬁ  cant advances in the knowledge of RSV biology, 
immunology, and epidemiology have been made in the last 40 
years, there continues to be signiﬁ  cant controversy over the 
optimum management of infants with acute RSV infection.
It has been suggested that RSV viral loads in the respira-
tory tract correlates with disease severity (Malley et al 1998; 
Buckingham et al 2002). However, as the disease progresses 
it is mainly the immune response responsible for the clinical 
manifestations and the persistence of symptoms (Malley 
et al 1998; Jafri et al 2004). Since the initial isolation of the 
virus, there have been considerable efforts to develop effec-
tive therapies for RSV infection: some directed against the 
virus such as ribavirin, others to modulate the inﬂ  ammatory 
response including steroids and anti-leukotrienes, and others 
to reduce the symptoms such as bronchodilators and heliox 
or nebulized hypertonic saline (Kuzik et al 2007).
To date, however, there is no speciﬁ  c treatment that 
is uniformly used for the management of this infection in 
previously healthy infants (Red Book 2006). Close monitor-
ing of the clinical evolution and supportive care of patients 
with intravenous ﬂ  uids and oxygen remain the mainstay of 
treatment of RSV disease in the great majority of patients 
(Mejias et al 2005a).
RSV prophylaxis
The lack of effective therapy against RSV infection makes 
prophylactic interventions the best strategy to avoid the acute 
and chronic complications of the disease (Palivizumab 1998; 
Simoes et al 2007). The peak incidence of severe RSV disease 
is between 2 and 3 months of age. The main risk factors for 
severe RSV disease in children include prematurity, CLD 
and CHD. Additional risk factors include male gender, birth 
during the ﬁ  rst half of the RSV season, younger age of RSV 
acquisition, and malnutrition (Parnes et al 2003). In addition 
there are several environmental factors that are associated 
with increased RSV disease severity such as crowding, pas-
sive exposure to tobacco smoke, day-care attendance, and 
the number of older school-age siblings (Chavez-Bueno et al 
2006). Thus, education of parents and other caregivers about 
methods to decrease the infant’s exposure to RSV and to other 
factors that may contribute to the severity of the infection 
must form the basis of any RSV prophylaxis program (Red 
Book 2006). Because RSV is transmitted by direct or close 
contact with contaminated secretions and the virus is known 
to persist for hours on environmental surfaces and for 30 
minutes or longer on hands, emphasis on hand hygiene is 
crucial (Red Book 2006).
Infants affected with RSV shed large quantities of virus 
in their nasopharyngeal secretions and saliva for up to 3 
weeks after the acute episode of RSV LRTI (Hall et al 1976). 
High-risk infants and children should not be exposed to 
individuals with respiratory infections and if at all possible, 
they should not be in settings (eg, child care centers) where 
such exposures are likely. Exposure to tobacco smoke must 
be eliminated since it has been associated with more severe 
RSV disease. These measures will have the added beneﬁ  t of 
decreasing transmission of other respiratory pathogens.Biologics: Targets & Therapy 2008:2(3) 435
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In addition to these hygienic measures, passive 
immunoprophylaxis of high-risk children initially with a 
polyclonal RSV Immune Globulin Intravenous (RSV-IGIV; 
RespiGam™, MedImmune Inc, Gaithersburg, MD, USA) and 
then with a monoclonal antibody, palivizumab (MEDI-493; 
Synagis®, MedImmune Inc, Gaithersburg, MD, USA), has 
been shown to reduce hospitalizations due to RSV infections, 
the surrogate marker for severe RSV lower respiratory tract 
disease in clinical trials. Despite this success, it is important 
to remember that most infants with severe RSV disease 
requiring hospitalization are previously healthy, term infants 
with no identiﬁ  able risk factors.
Passive immunization
Polyclonal antibodies
RSV-IGIV is a hyperimmune polyclonal human intrave-
nous antibody preparation that was prepared from multiple 
donors. It was licensed by the Food and Drug Administra-
tion (FDA) in 1996. Two multicenter, randomized clinical 
trials demonstrated that monthly RSV-IGIV infusions of 
750 mg/kg in children with either prematurity (35 weeks 
of gestation, 6 months of age) or BPD (age 24 months) 
resulted in a 41%–63% reduction in RSV hospitalization 
(Groothius et al 1993; PREVENT 1997). An additional 
multicenter trial of RSV-IGIV in children 48 months of age 
with CHD showed a nonsignﬁ  cant 31% decrease in RSV hos-
pitalizations. A signiﬁ  cant increase in cyanotic episodes and 
cardiac surgery-related deaths occurred among those children 
with cyanotic CHD and right to left shunt (Simoes et al 1998). 
Thus, RSV-IVIG should not be used in children with CHD. 
Other disadvantages of prophylaxis with RSV-IGIV include 
the need for intravenous access; the ﬂ  uid load (15 mL/kg) 
required to deliver the drug, the potential for transmission of 
blood-borne pathogens, and the interference with the antibody 
response to live-virus vaccines. On the other hand, since it 
is a polyclonal preparation it also offered protection against 
a variety of pathogens besides RSV. RespiGam, the initially 
licensed RSV-IVIG preparation, is no longer marketed in the 
US; its use has been replaced by palivizumab.
Monoclonal antibodies
Palivizumab
Palivizumab is a neutralizing humanized mouse IgG1 mono-
clonal antibody directed against one of the two most antigeni-
cally stable sites of the F glycoprotein of the virus, site A 
(Beeler et al 1989). It blocks the fusion of the virus to the host 
epithelial cell. Palivizumab was completely engineered in the 
laboratory, and as such 95% is of human origin and only 5% 
murine. Due to the more conserved nature of these epitopes 
within the F protein, palivizumab shows a high degree of 
cross-reactivity among RSV subtypes A and B and is about 
50-fold more potent than polyclonal preparations (Johnson 
et al 1997). It was licensed by the FDA in 1998 (Palivizumab 
1998) for prevention of severe RSV disease in preterm infants 
and children with CLD. More recently, palivizumab was 
also approved for use in children with hemodynamically 
signiﬁ  cant CHD (Feltes et al 2003). The safety and efﬁ  cacy 
of palivizumab in high-risk infants and children was demon-
strated in 2 large randomized, placebo-controlled trials.
The IMpact Trial assessed the safety and efﬁ  cacy of 
intramuscular palivizumab at a dose of 15 mg/kg provided 
every 30 days during the RSV season for prevention of 
RSV hospitalization (Palivizumab 1998). This international, 
randomized, double blind, placebo-controlled study enrolled 
1,502 children who were either were 1) 35 weeks of gestation 
and 6 months of age, or 2) 24 months of age with CLD that 
required medical treatment (ie, supplemental oxygen, steroids, 
bronchodilators, or diuretics) within the previous 6 months at 
the start of the RSV season. Palivizumab prophylaxis resulted 
in a 55% overall decrease of RSV-related hospitalization 
compared to placebo-treated controls. Subgroup analyses by 
degree of prematurity, and by absence of CLD also yielded 
signiﬁ  cant reductions in RSV hospitalization. Palivizumab 
prophylaxis also demonstrated clinical efﬁ  cacy in several 
secondary endpoints: it reduced the length of hospitalization 
for RSV infection, decreased requirement for supplemental 
oxygen, decreased number of days of moderate or severe 
lower respiratory tract illness, and decreased requirement for 
hospitalization in the intensive care unit.
Data obtained from the Palivizumab Outcomes Registry, 
a prospective nationwide registry of 2,116 high-risk children 
who received palivizumab after its FDA licensure, demon-
strated total RSV hospitalization rates of 2.9% compare to 
the 4.8% reported in the Impact-RSV trial. Thus, the post-
licensure real world experience has shown even greater efﬁ  -
cacy in reducing hospitalization rates in high-risk children. 
The majority of the RSV hospitalizations reported to the 
Registry occurred between the ﬁ  rst and second doses, pos-
sibly reﬂ  ecting lower trough concentrations of palivizumab 
following a single dose (Parnes et al 2003)
Palivizumab also has shown beneﬁ  t in children with CHD. 
From 1998 to 2002 during 4 consecutive RSV seasons, an 
international, multicenter, randomized, double blind, placebo-
controlled study was conducted. This trial evaluated the safety, 
tolerance and efﬁ  cacy of palivizumab for prevention of RSV 
hospitalization in 1,287 children who were 24 months of age Biologics: Targets & Therapy 2008:2(3) 436
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with hemodynamically signiﬁ  cant CHD (Feltes et al 2003). 
Eligible children were 24 months old and were stratiﬁ  ed 
at entry to a cyanotic or acyanotic group. This study dem-
onstrated that palivizumab was safe in children with cardiac 
disease and that its use decreased by 45% the rate of RSV 
hospitalization. Although the trial was not powered to analyze 
differences among subgroups, hospitalizations were reduced 
by 29% in those with cyanotic CHD while among those chil-
dren with acyanotic lesions there was a signiﬁ  cant reduction 
of 58%. In addition, among all study children, there was a 
56% decrease in total days of RSV-associated hospitalization 
per 100 children and a 73% decrease in total RSV-associated 
hospital days with supplemental oxygen per 100 children. 
The percentage of children who died was similar in both the 
palivizumab (3.3%) and placebo (3.7%) groups. None of the 
fatalities were attributed to the study drug. Palivizumab serum 
concentrations decreased by 58% after cardiopulmonary 
bypass, and it is recommended that a postoperative dose of 
palivizumab be provided in those children who continue to 
require prophylaxis after such surgery.
The results of this study led to approval of palivizumab by 
the FDA for prophylaxis in this high-risk group of children. 
Similarly, the palivizumab Outcomes Registry prospectively 
collected data on 1,490 subjects with CHD who received RSV 
prophylaxis with palivizumab from 2000 to 2004. This study 
demonstrated that total RSV hospitalization rates in those 
subjects with either cyanotic or acyanotic CHD who received 
palivizumab were low and decreased from the ﬁ  rst to the 
fourth season (4.3% vs 1.5% respectively) (Cohen et al 2008), 
conﬁ  rming the efﬁ  cacy of palivizumab in this setting.
Palivizumab has not been associated with an increased 
risk of localized or systemic adverse events. Speciﬁ  cally, 
there has been no signiﬁ  cant difference in hematologic, 
renal, or hepatic abnormalities between palivizumab and 
placebo recipients, even with repeated dosing during a sec-
ond season of prophylaxis. In the IMpact trial, fever, mild 
injection site erythema, induration or swelling occurred in 
3% of recipients. Antibodies to palivizumab have been seen 
transiently among both drug and placebo recipients, but this 
has not been associated with adverse reactions. Following 
licensure of palivizumab, anaphylaxis after re-exposure and 
acute hypersensitivity reactions on initial and re-exposure to 
palivizumab have been reported rarely (1 in 100,000).
Recommendations for palivizumab 
prophylaxis
The American Academy of Pediatrics (AAP) has issued a 
policy statement for the use of palivizumab for prophylaxis 
of RSV infections in high-risk children (AAP 2003). 
Palivizumab is administered intramuscularly at a dose of 
15 mg/kg monthly (every 30 days) during the RSV season, 
which typically in the US starts in November and ends in 
March or April. A maximum of 5 doses is generally sufﬁ  cient 
prophylaxis during one season. This recommended dose and 
schedule assures the maintenance of serum palivizumab 
concentrations of 40 μg/mL, a concentration that has 
shown to decrease pulmonary RSV replication in the cotton 
rat model by 100-fold (Johnson et al 2007). Different 
studies have shown that protective palivizumab serum 
through concentrations (40 μg/mL) increased after the 
second dose of 15 mg/kg/month (Saez-Llorens et al 1998). 
Thus, it is important to avoid delaying administration of the 
second injection dose in order to achieve adequate protec-
tive serum levels. High-risk infants and children should 
receive palivizumab before hospital discharge. Once a child 
qualiﬁ  es for prophylaxis, administration should continue 
throughout the RSV season and not stop at the point he or 
she reaches any certain age. Since some children experience 
more than one RSV infection during a given season, infants 
and children who develop a RSV infection while receiving 
palivizumab should continue to receive prophylaxis after 
recovery from their acute infection. Palivizumab can be given 
with routine immunizations since it does not interfere with 
the immunologic response to vaccines. Palivizumab is now 
available in a preservative-free liquid formulation with either 
50 mg or 100 mg of palivizumab (Synagis®, MedImmune, 
Inc.) in 0.5 mL or 1 mL vials, respectively (Palivizumab 
2005). The liquid form is stable at refrigerator temperatures. 
The lyophilized form continues to be available. Palivizumab 
can be given with routine childhood immunizations since 
it does not interfere with the immunologic response to 
vaccines. Although RSV mutants resistant to palivizumab 
have been derived in the laboratory (Zhao et al 2004a, b), no 
palivizumab-resistant mutants have been described in humans 
(Devincenzo et al 2004).
The recommendations issued by the AAP for the use of 
palivizumab in high-risk children are provided in Figure 1 
(AAP 2003). For infants born between 32 weeks, 1 day and 
35 weeks, 0 days of gestation, the AAP recommends that 
prophylaxis be considered only if 2 or more risk factors are 
present. Although palivizumab has been shown to decrease 
RSV hospitalization in these infants, and infants 33–35 weeks 
of gestation may have adverse hospital outcomes secondary 
to RSV (Beyer et al 2004), the health-care expenditures of 
prophylaxis makes routine administration of palivizumab 
problematic in this group of infants.Biologics: Targets & Therapy 2008:2(3) 437
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Children with hemodynamically signiﬁ  cant CHD are 
candidates for prophylaxis. However, the degree of physi-
ologic cardiovascular compromise must be assessed. Children 
with the following cardiac lesions are not at increased risk 
for severe RSV infection and generally are not considered 
candidates for immunoprophylaxis: 1) hemodynamically 
insigniﬁ  cant CHD such as secundum atrial septal defect, 
small ventricular septal defect, pulmonic stenosis, uncom-
plicated aortic stenosis, mild coarctation of the aorta, and 
patent ductus arteriosus; 2) lesions adequately corrected by 
surgery unless there is continued requirement of medication 
for congestive heart failure; and 3) mild cardiomyopathy not 
requiring medical therapy.
Motavizumab
Monoclonal antibody variants derived from palivizumab 
have been generated by modifying antibody binding kinetics 
that resulted in increased binding avidity and viral neutraliza-
tion activity (Mejias et al 2004b). One of these antibodies, 
motavizumab (Medi-524 or Numax™), a second-generation 
mAb, has been shown to decrease lower and upper airway 
RSV loads in cotton rats by 50- to 110-fold compared with 
palivizumab.
A recent multinational, randomized double blind, phase 
III clinical trial assessed the safety and relative efﬁ  cacy of 
motavizumab and palivizumab at reducing RSV speciﬁ  c 
hospitalizations and outpatient medically attended lower 
respiratory tract infections (LRIs). Over 2 consecutive 
RSV seasons 6,635 pre-term infants 35 weeks gestation 
and 6 months of age or preterm infants 24 months of age 
with CLD requiring treatment were randomized to receive 
palivizumab (n = 3,3326) or motavizumab (n = 3,329) at 
15 mg/kg IM monthly, and followed for 150 days. Admin-
istration of either mAb resulted in very low rates of RSV 
hospitalization (1.4% vs 1.9% for motavizumab vs palivi-
zumab respectively). However, motavizumab showed better 
protection against RSV outpatient medically attended LRIs 
with a 50% relative reduction in RSV speciﬁ  c LRIs compared 
with palivizumab (2% vs 3.9%, respectively (p  0.01) 
(Carbonell-Estrany et al 2007). A phase III clinical study is 
ongoing to evaluate safety and efﬁ  cacy of motavizumab ver-
sus palivizumab at reducing severe RSV disease in patients 
with hemodinamically signiﬁ  cant CHD. Most recently, a 
third-generation mAb, Numax-YTE, has been generated 
with the intent to extend the serum half-life of the mAbs in 
humans. If successfully developed, this drug may offer the 
2 years at start of RSV season?
Yes 
No
Palivizumab not recommended 
Prematurity, BPD
1 CLD
2 OR CHD
3
Prematurity:
1) GA4 ≤ 32 wks, 0 d:
GA ≤ 28 wks gestation and ≤ 12 months of age*
29–32 wks gestation and ≤ 6 months of age*
2) 32 wks, 1 d and 35 wks 0 d and < 6 months of age:*
If ≥ 2 risk factors present:
oChild care attendance 
oSchool-aged siblings 
oExposure to environmental air pollutants 
(excludes tobacco smoke) 
oCongenital abnormalities of the airways 
o Severe neuromuscular disease 
Yes
BPD (CLD): 
< 2 yrsa and has required
medical therapy (ie, 
supplemental oxygen, 
bronchodilator, diuretic or 
corticosteroid therapy) for BPD 
in past 6 months
a
CHD:
≤ 24 months:a
o On medication for 
congestive heart failure 
o Moderate to severe 
pulmonary hypertension
o Cyanotic lesion
Palivizumab recommended 
a At start of RSV season 
1BPD, bronchopulmonary dysplasia
2CLD, chronic lung disease of prematurity 
3CHD, congenital heart disease 
4Gestational age 
Age ≤
Figure 1 Recommendations for respiratory syncytial virus (RSV) prophylaxis in high-risk children.Biologics: Targets & Therapy 2008:2(3) 438
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opportunity for less frequent dosing, obviating the need for 
the monthly treatments that are required with palivizumab 
(Mejias et al 2004a).
Prophylaxis in other high-risk populations
There are other several high-risk groups that may beneﬁ  t from 
prophylaxis; however insufﬁ  cient data exist to recommend 
its routine use. In these situations physicians caring for these 
patients make individualized decisions on the basis of the 
available data and the unique situation of each patient.
a) Viral respiratory infections, including RSV infections, 
are commonly associated with acute pulmonary exacer-
bations in patients with cystic ﬁ  brosis (CF) (Wang et al 
1984). The short-term morbidity of RSV infection in 
young children with CF (length of hospitalization and 
ICU stay) appears to be comparable to that of children 
with CLD (Arnold et al 1999). A recent retrospective 
cohort study in 75 children diagnosed with CF at 18 
months of age (35 of whom received palivizumab pro-
phylaxis) showed a reduced but not signiﬁ  cant length of 
hospitalization during the ﬁ  rst RSV season in patients that 
received the prophylaxis, suggesting that young children 
with CF may beneﬁ  t from the use of palivizumab (Giebels 
et al 2008). Results are pending of a phase IV multicenter, 
randomized, double blind, placebo-controlled study on 
the safety and tolerance of palivizumab in children 24 
months of age with cystic ﬁ  brosis.
b) RSV can cause serious respiratory illness among solid 
organ transplant (SOT) patients, yet there is no standard 
recommendation for RSV immunoprophylaxis. To learn 
the current practices for the prevention of RSV disease 
in pediatric SOT candidates and recipients in the US, a 
24-questionnaire survey was mailed to 108 SOT programs 
in 2006. The types of SOT programs included: liver, 
heart, lung, intestine, and heart-lung types of transplants. 
Among the programs that completed the survey, 49% 
reported the use of prophylaxis with palivizumab with 
similar rates among recipients of all organ types. No data 
on RSV hospitalizations and outcomes were obtained 
and this information is crucial to develop a more rational 
approach to RSV immunoprophylaxis in these high-risk 
patients (Fonseca-Aten et al 2007).
Potential long-term beneﬁ  ts of anti-RSV 
prophylaxis
In addition to reducing the acute morbidity, there also may 
be potential beneﬁ  ts from prevention of long term RSV 
sequelae such as recurrent wheezing and asthma. In an animal 
model of RSV infection, prophylactic administration of both 
palivizumab and motavizumab signiﬁ  cantly reduced the 
development of airway hyperreactivity and chronic airway 
inﬂ  ammation (Mejias et al 2004b, 2005b). In humans, a 
recent double cohort multicenter study showed that preterm 
infants who received palivizumab prophylaxis during their 
ﬁ  rst RSV season had a signiﬁ  cant lower risk of subsequent 
recurrent wheezing during a 24-month follow-up compared 
with age-matched controls who did not receive prophylaxis 
(Simoes et al 2007). Despite its limitations this is a crucial 
study that demonstrates for the ﬁ  rst time in humans that 
interventions directed against acute RSV can provide a 
long-term beneﬁ  t. Future, prospective, randomized, placebo-
controlled studies should be developed to conﬁ  rm these 
important ﬁ  ndings.
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